In this issue:
MANIFEST-2: Front-line pelabresib plus ruxolitinib promising
Optimal ruxolitinib dosing linked to improved outcomes
Outcome of splenectomy in JAK2 inhibitor treated patients
New machine learning model may enhance transplant risk stratification
Incorporation of molecular aberrations into risk stratification improves transplant decisions
Anti-fibrotic activity of PXS-5505 in advanced myelofibrosis
Pre-transplant ruxolitinib not associated with increased risk for GvHD
Post-transplant JAK2 V617F surveillance aids in the prediction of relapse
Please login below to download this issue (PDF)